
Illumina (ILMN) Stock Forecast & Price Target
Illumina (ILMN) Analyst Ratings
Bulls say
Illumina has demonstrated a strong ability to increase revenue historically, even while driving down the cost of sequencing, a testament to the demand elasticity in its market. With a focus on achieving high single-digit revenue growth by 2027, supported by an innovative roadmap of multiomic technologies and workflows, Illumina remains well-positioned for future expansion. Additionally, despite potential short-term challenges in international markets, the company expects a significant increase in earnings per share, projecting approximately 14% growth in 2026.
Bears say
Illumina's stock faces a negative outlook primarily due to lowered guidance for non-GAAP diluted EPS, reflecting concerns over reduced earnings contributions from the Chinese market and persistent macroeconomic trends. The company has experienced a significant decline in stock value, reportedly down about 40%, as fears surrounding its ability to operate in China and potential funding cuts from the NIH have intensified. Additionally, if Illumina fails to maintain its market share in the next-generation sequencing (NGS) market and cannot achieve revenue or earnings growth consistent with its peers, it risks trading at a continued discount relative to its competitors.
This aggregate rating is based on analysts' research of Illumina and is not a guaranteed prediction by Public.com or investment advice.
Illumina (ILMN) Analyst Forecast & Price Prediction
Start investing in Illumina (ILMN)
Order type
Buy in
Order amount
Est. shares
0 shares